HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

sominone

structure in first source

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tohda, Chihiro: 4 articles (04/2011 - 03/2006)
2.	Matsuya, Yuji: 2 articles (04/2011 - 09/2009)
3.	Joyashiki, Eri: 1 article (04/2011)
4.	Nemoto, Hideo: 1 article (09/2009)
5.	Teshigawara, Kiyoshi: 1 article (09/2009)
6.	Yamada, Masashi: 1 article (09/2009)
7.	Yamakawa, Yu-ichiro: 1 article (09/2009)
8.	Komatsu, Katsuko: 1 article (03/2006)
9.	Kuboyama, Tomoharu: 1 article (03/2006)

Related Diseases

1.	Amyloid Plaque 04/01/2011 - "Sominone treatment significantly enhanced axonal densities in the frontal cortex and parietal cortex but had no effects on amyloid plaque number and activated microglia. " 04/01/2011 - "These results suggest that memory deficits in AD may be improved by sominone independently of reducing amyloid plaques and neuroinflammation."
2.	Memory Disorders (Memory Loss) 04/01/2011 - "However, it had not been reported that sominone could recover memory deficits in a severe Alzheimer's disease (AD) model animal. " 04/01/2011 - "These results suggest that memory deficits in AD may be improved by sominone independently of reducing amyloid plaques and neuroinflammation."
3.	Neuroinflammatory Diseases 04/01/2011 - "These results suggest that memory deficits in AD may be improved by sominone independently of reducing amyloid plaques and neuroinflammation."
4.	Alzheimer Disease (Alzheimer's Disease) 04/01/2011 - "Sominone improves memory impairments and increases axonal density in Alzheimer's disease model mice, 5XFAD." 04/01/2011 - "However, it had not been reported that sominone could recover memory deficits in a severe Alzheimer's disease (AD) model animal. " 09/03/2009 - "Synthesis of sominone and its derivatives based on an RCM strategy: discovery of a novel anti-Alzheimer's disease medicine candidate "denosomin"." 03/01/2006 - "These data suggest that orally administrated withanoside IV may ameliorate neuronal dysfunction in Alzheimer's disease and that the active principle after metabolism is sominone."
5.	Gliosis 08/01/2008 - "The loss of CNS myelin and increase in reactive gliosis were not affected by withanoside IV. Additionally, sominone, an aglycone of withanoside IV, was identified as the main metabolite after oral administration of withanoside IV in mice. "

Related Drugs and Biologics

1.	withanoside IV
2.	denosomin

Related Therapies and Procedures

1.	Oral Administration